They don’t agree on the details, but both Republicans and Democrats in the Senate are ready to ramp up oversight of a federal drug discount program that hospitals generally support — and drug makers tend to want to rein in.
On its face, the increasing congressional scrutiny seems like a win for the pharmaceutical industry, which has bucked against the status quo. But lawmakers at a Tuesday hearing on the program, known as 340B, signaled an interest in taking aim at both industries.
About the Author Reprints
